Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 13/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6477169 | 0.93 | PPARG (0.64) | PPARGSIGMAR1TP53PPARANPC1 | |
| SCHEMBL6484603 | 0.92 | PPARG (0.55) | PPARGSIGMAR1TP53MAPTPPARA | |
| SCHEMBL6476453 | 0.91 | PPARG (0.60) | PPARGSIGMAR1TP53PPARANPC1 | |
| SCHEMBL6531209 | 0.90 | PPARG (0.59) | PPARGSIGMAR1TP53PPARANPC1 | |
| SCHEMBL5913753 | 0.88 | PPARG (0.61) | PPARGSIGMAR1TP53PPARANPC1 | |
| SCHEMBL5913749 | 0.88 | PPARG (0.61) | PPARGSIGMAR1TP53PPARANPC1 | |
| SCHEMBL6476460 | 0.88 | PPARG (0.57) | PPARGSIGMAR1TP53PPARANPC1 | |
| SCHEMBL6484848 | 0.88 | PPARG (0.53) | PPARGSIGMAR1TP53MAPTPPARA | |
| SCHEMBL6476336 | 0.87 | PPARG (0.47) | PPARGTP53MAPTPPARANPC1 | |
| SCHEMBL6476342 | 0.87 | PPARG (0.47) | PPARGTP53MAPTPPARANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6919362-B2 | Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2005-07-19 | — | — | US | disclosed |
| EP-1252150-B1 | HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SERVIER LAB (FR) | 2003-06-04 | — | — | EP | disclosed |
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | LES LABORATOIRES SERVIER (FR) | 2003-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040533-A1 | Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same | CYP2F1, CYP11B2, CYP4B1 | PPARG 414/4885SIGMAR1 153/4885TP53 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.